Advanced BioMedical Technologies, Inc.

As of July 31, 2021, Advanced BioMedical Technologies, Inc. carries a market capitalization of 5.55M, placing it among publicly traded companies globally. Its enterprise value stands at 5.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2021, Advanced BioMedical Technologies, Inc. has 70.22M shares outstanding.

These figures are as of July 31, 2021. The price-to-sales ratio is 50.51, and the price-to-book ratio stands at -0.68.

These figures are as of July 31, 2021. The EV/Sales ratio of 50.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.55M versus a market cap of 5.55M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2021, Advanced BioMedical Technologies, Inc. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -0.13, indicating conservative leverage, while an interest coverage ratio of -1.19 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended July 31, 2021. Return on assets (ROA) is negative at -222.13, reflecting losses generated across the asset base. The company generates approximately 6,461.41 in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.21 indicates how many times Advanced BioMedical Technologies, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 4, 2026, Advanced BioMedical Technologies, Inc.'s stock has gained approximately 400.00% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.07.

Over the twelve months ended July 31, 2021, Advanced BioMedical Technologies, Inc. generated 109,844.00 in revenue and converted that into -753,180.00 in net income, yielding earnings per share of -0.01. EBITDA reached -373,963.00, while operating income came in at -423,199.00.

As of July 31, 2021, Advanced BioMedical Technologies, Inc. holds 6,983.00 in cash and equivalents against 10,826.00 in total debt, resulting in a net debt position of -6,983.00. Total book value stands at -8.18M, with working capital of -8.34M providing operational flexibility.

Advanced BioMedical Technologies, Inc. produced 9,134.00 in operating cash flow over the twelve months ended July 31, 2021. After subtracting -52,463.00 in capital expenditures, free cash flow totaled -43,329.00 - equivalent to 0.00 per share.

Over the twelve months ended July 31, 2021, Advanced BioMedical Technologies, Inc. posted a gross margin of 74.32, reflecting its pricing power and cost economics. The operating margin of -385.27 and net profit margin of -685.68 provide insight into operational efficiency.

Over the twelve months ended July 31, 2021, Advanced BioMedical Technologies, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.78: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.40, meaning Advanced BioMedical Technologies, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Advanced BioMedical Technologies, Inc.'s most recent stock split took place on March 13, 2009 with a 1:10 split ratio.

As of July 31, 2021, Advanced BioMedical Technologies, Inc. has an Altman Z-Score of -66.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.